{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:04:08Z","timestamp":1789790648789,"version":"4.0.1"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7992-26","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:11:44Z","timestamp":1789423904000},"source":"Crossref","is-referenced-by-count":0,"title":["Paraneoplastic Neurological Syndrome in a Patient with Limited-stage Small-cell Lung Cancer Receiving Durvalumab Maintenance after Concurrent Chemoradiotherapy: A Case Report"],"prefix":"10.2169","author":[{"given":"Daisuke","family":"Abe","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Matsuzawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Hirunagi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine, Japan"},{"name":"Nagoya University Institute for Advanced Research, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsaku","family":"Hayai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayasu","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichidai","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Shindo","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Soomro Z, Youssef M, Yust-Katz S, Jalali A, Patel AJ, Mandel J. Paraneoplastic syndromes in small cell lung cancer. J Thorac Dis 12: 6253-6263, 2020.","DOI":"10.21037\/jtd.2020.03.88"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med 391: 1313-1327, 2024.","DOI":"10.1056\/NEJMoa2404873"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Graus F, Vogrig A, Mu\u00f1iz-Castrillo S, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 8: e1014, 2021.","DOI":"10.1212\/NXI.0000000000001014"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 349: 1543-1554, 2003.","DOI":"10.1056\/NEJMra023009"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lancaster E, Dalmau J. Neuronal autoantigens--pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 8: 380-390, 2012.","DOI":"10.1038\/nrneurol.2012.99"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Graus F, Keime-Guibert F, Re\u00f1e R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124: 1138-1148, 2001.","DOI":"10.1093\/brain\/124.6.1138"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nassar AH, El Zarif T, Khalid AB, et al. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. J Immunother Cancer 12: e008724, 2024.","DOI":"10.1136\/jitc-2023-008724"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sato Y, Fujiwara S, Hata A, et al. Clinical impact of pre-existing autoantibodies in patients with SCLC treated with immune checkpoint inhibitor: a multicenter prospective observational study. JTO Clin Res Rep 4: 100608, 2023.","DOI":"10.1016\/j.jtocrr.2023.100608"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Farina A, Villagr\u00e1n-Garc\u00eda M, Vogrig A, et al. Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol 23: 81-94, 2024.","DOI":"10.1016\/S1474-4422(23)00369-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Shechtman Y, Shalata W, Khoury R, Mahajna A, Weller B, Agbarya A. Encephalitis induced by durvalumab during treatment of metastatic small-cell lung cancer: illustrative case and review of the literature. J Immunother 44: 243-247, 2021.","DOI":"10.1097\/CJI.0000000000000362"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Li J, Jiang J, Lv J, et al. Anti-\u03b3-aminobutyric acid type B receptor antibody-associated encephalitis after 2 cycles of durvalumab therapy in a patient with small cell lung cancer: a case report. Onco Targets Ther 14: 5227-5236, 2021.","DOI":"10.2147\/OTT.S337331"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wang L, Lou H, Li B, Li J, Yang YM. Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer. Invest New Drugs 40: 151-156, 2022.","DOI":"10.1007\/s10637-021-01154-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Machiyama H, Minami S. Durvalumab for extensive-stage small-cell lung cancer with Lambert-Eaton myasthenic syndrome. J Med Cases 14: 71-75, 2023.","DOI":"10.14740\/jmc4043"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Moss TT, Stavem K, Aandahl A, et al. Case report: limbic encephalitis following treatment with durvalumab for small-cell lung cancer. Front Immunol 14: 1278761, 2023.","DOI":"10.3389\/fimmu.2023.1278761"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ishibashi N, Tabata T, Nonomura R, et al. Efficacy of durvalumab plus chemotherapy in small-cell lung cancer with Lambert-Eaton myasthenic syndrome. Respir Med Case Rep 47: 101974, 2024.","DOI":"10.1016\/j.rmcr.2023.101974"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Seki T, Baba K, Hayashi T, et al. Lung cancer wherein durvalumab induced both anti-CRMP-5 antibody-related paraneoplastic neurological syndromes and neurological adverse events. Intern Med 63: 1009-1014, 2024.","DOI":"10.2169\/internalmedicine.1771-23"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Saitou A, Shioya M, Nagahisa Y, et al. Small-cell lung carcinoma with gastrointestinal pseudo-obstruction as a paraneoplastic neurological syndrome elicited by an immune checkpoint inhibitor. Intern Med 63: 2059-2062, 2024.","DOI":"10.2169\/internalmedicine.2648-23"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Qian YL, Jiang Y, Gong YH, et al. Autoimmune encephalitis following treatment with durvalumab for small-cell lung cancer. J Int Med Res 52: 3000605241287015, 2024.","DOI":"10.1177\/03000605241287015"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shi GQ, Lian HN, Wang H, Xia JQ, Ma LJ, Zhou J. Case report: immune checkpoint inhibitor-induced paraneoplastic neurological syndrome in two patients: a case series. Front Oncol 14: 1404829, 2024.","DOI":"10.3389\/fonc.2024.1404829"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nakahara L, Matsuura S, Suzuki R, et al. Immune checkpoint inhibitor-induced autoimmune limbic encephalitis with positivity for anti-Hu antibodies in a patient with small-cell lung cancer: a case report and literature review. Respirol Case Rep 12: e70070, 2024.","DOI":"10.1002\/rcr2.70070"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Morinaga D, Kitai H, Sato H, et al. Limited-stage small-cell lung cancer with severe paraneoplastic limbic encephalitis successfully treated with chemoradiotherapy followed by immune checkpoint inhibitor maintenance therapy: a case report. Clin Lung Cancer 27: 121-125, 2026.","DOI":"10.1016\/j.cllc.2026.01.011"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Zhang L, Fan S, Wang J, Ren H, Guan H. Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review. J Neurol 272: 249, 2025.","DOI":"10.1007\/s00415-025-12992-7"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Graus F, Dalmau J, Ren\u00e9 R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 15: 2866-2872, 1997.","DOI":"10.1200\/JCO.1997.15.8.2866"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7992-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:31:06Z","timestamp":1789788666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7992-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":23,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7992-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7992-26"}}